Maximum quantity allowed is 999
Please select the quantity
CAS RN: 122111-03-9 | Product Number: G0367
Gemcitabine Hydrochloride
×
![]()
×
Purity: >98.0%(HPLC)(N)
Synonyms:
- 2'-Deoxy-2',2'-difluorocytidine
- dFdC
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 100MG |
$78.00
|
17 | ≥100 | Contact Us | |
| 1G |
$399.00
|
37 | ≥100 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | G0367 |
| Purity / Analysis Method | >98.0%(HPLC)(N) |
| Molecular Formula / Molecular Weight | C__9H__1__1F__2N__3O__4·HCl = 299.66 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 122111-03-9 |
| Related CAS RN | 95058-81-4 |
| Reaxys Registry Number | 5386970 |
| PubChem Substance ID | 125307627 |
| SDBS (AIST Spectral DB) | 52896 |
| Merck Index (14) | 4386 |
| MDL Number | MFCD01735988 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Specific rotation [a]20/D | +46.0 to +49.0 deg(C=1, H2O) |
Properties (reference)
| Melting Point | 292 °C |
| Specific Rotation | 48° (C=1,H2O) |
| Maximum Absorption Wavelength | 268(H2O) nm |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H361 : Suspected of damaging fertility or the unborn child. H373 : May cause damage to organs through prolonged or repeated exposure. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | HA3840000 |
Transport Information:
| H.S.code* | 2940.00-000 |
Application
Autophagy research / Mitophagy research
References
- Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
Application
Gemcitabine Hydrochloride: A Fluorinated Deoxycytidine Analog with Antitumor Activity
Gemcitabine [G0544] and its hydrochloride are fluorinated deoxycytidine analogs with antitumor activity against solid tumors. Once inside the cell, gemcitabine is rapidly phosphorylated by deoxycytidine kinase to form the active metabolites gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). dFdCDP inhibits ribonucleotide reductase, which is responsible for producing the deoxynucleotides required for DNA synthesis and repair. dFdCTP can be incorporated into DNA, leading to inhibition of DNA synthesis. On the other hand, a concomitant treatment with gemcitabine and cisplatin [D3371] is used for the treatment of several different types of cancer. Cisplatin acts by formation of platinum (Pt)-DNA adducts; gemcitabine acts by dFdCTP incorporation into DNA, subsequently leading to inhibition of exonuclease and DNA repair. (The product is for research purpose only.)
References
- Gemcitabine: metabolism, mechanisms of action, and self-potentiation (a review)
- Gemcitabine. A review of its pharmacology and clinical potential in non-small-cell lung cancer and pancreatic cancer
- Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine) (a review)
- Synergistic interaction between cisplatin and gemcitabine in vitro
- Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection
- Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.